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Introduction
Detailed epidemiological studies and neuro-imaging
have provided important insights into the natural course
of and prognostic factors for multiple sclerosis (MS).
However, MS is a complex, most likely polygenetic dis-
order, in which several genes interact to result in a het-
erogeneous pathogenesis; our ability to predict different
courses of the disease, and especially its response to
treatment, is still very limited.The discovery of new gene
targets may be key to developing novel and effective
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natural course and prognostic
factors of multiple sclerosis (MS),
but our ability to predict different
courses of the disease, and espe-
cially its response to treatment, is
still very limited. Pharmacoge-
netic, pharmacogenomic and pro-
teomic studies aim to assess gene
and protein function in disease
and promise to help to fill this im-
portant gap in our knowledge.
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Such studies may increase our un-
derstanding of disease mecha-
nisms and responses to therapeu-
tic compounds. Large-scale
transcriptional expression profil-
ing can be performed using gene
chip microarrays; this technology
allows screening for differentially
expressed genes without having
well-defined underlying hypothe-
ses (“discovery-driven research”).
To complement the technique, real
time reverse transcription and
polymerase chain reaction (RT-
PCR) can be used for more tar-
geted profiling and provides quan-
titative data on pre-selected genes.
However, to maximise their clinical
utility, expression profiling results
need to be combined with well-
documented clinical and imaging
data.
Two forthcoming studies will in-
vestigate the long-term effects of
early treatment with interferon
beta-1b (IFNβ) on the course of
MS. The BENEFIT (BEtaseron®/
Betaferon® in Newly Emerging MS
for Initial Treatment) study will
incorporate pharmacogenetic and
pharmacogenomic analyses to
determine the genetic elements
controlling treatment response.
BEST-PGx (Betaferon®/Betaseron®
in Early relapsing-remitting MS
Surveillance Trial – Pharmacoge-
nomics) is an exploratory 2-year
study that will investigate the value
of RNA expression profiling and
pharmacogenetics in predicting
treatment response to IFNβ in pa-
tients with early relapsing MS. The
main goal of BEST-PGx is the iden-
tification of differences in gene
expression profiles of patients
showing differential treatment
responses. In addition, this study
may reveal new information rele-
vant to the mechanism of action of
interferon treatment in MS and
also to differences in the underly-
ing pathology of the immune
system. These data may help us
approach the goal of a really “indi-
vidualised therapy” with increased
efficacy, reduced adverse drug re-
actions and more efficient use of
healthcare resources.
■ Key words genomics · interferon
beta-1b · multiple sclerosis ·
proteomics · pharmacogenetics
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therapeutic agents for MS. Together with improvements
in imaging techniques, genomics and proteomics are
important new tools that promise to help in elucidating
the pathogenesis of this complex disease.
The need for markers – questions raised 
in clinical studies
Based on magnetic resonance imaging (MRI) and neu-
ropathological studies in patients with MS, there is evi-
dence that progressive disability is associated with cu-
mulative and irreversible axonal loss [5, 45]. Data also
suggest that axonal loss and cerebral atrophy both occur
early in the course of the disease, at a time when there is
either no disability, or only mild disablement [13, 40].
Further evidence comes from Brex et al. [7] who showed,
using natural history studies, a modest correlation be-
tween changes in lesion volume in the first 5 years and
disability after 14 years in patients presenting with clin-
ically isolated syndrome (CIS) suggestive of MS.
Data from two studies examining early intervention
at a diagnosis of CIS – CHAMPS (Controlled High-risk
subjects Avonex® MS Prevention Study) and ETOMS
(Early Treatment Of MS) – demonstrated the impor-
tance of early intervention with interferon beta (IFNβ)
as well as the value of MRI as a prognostic marker [1, 2,
12, 24, 27]. The CHAMPS study showed that in patients
with high MRI lesion burden and evidence of inflam-
mation, the Kaplan-Meier estimate of the cumulative
probability of developing clinically definite MS (CDMS)
was 21 % in the IFNβ-1a group, compared with 56 % in
the placebo group [2, 24, 27]. A high MRI lesion burden
and evidence of inflammation was defined as at least
nine T2-hyper-intense lesions and at least one Gd-en-
hanced lesion on the initial (baseline) MRI scan.
The ETOMS study found that a high T2 lesion num-
ber at presentation is associated with polysymptomatic
events and attack severity [1, 12]. Conversion to CDMS
occurred in 43 % of patients with Gd-enhancement
compared with 34 % without (P = 0.085). When the lack
of a Gd-enhanced lesion was substituted by the presence
of nine or more T2 lesions, the predictive value in-
creased (41 % vs. 11 %; P = 0.008).
The outcomes from CHAMPS and ETOMS pose a se-
ries of additional questions that need to be addressed in
terms of pinpointing whether dose and frequency of ad-
ministration are critical in the early phase of MS. There
is also a need to determine the long-term effects and im-
pact of early intervention on the underlying pathology.
Another important question raised by the data from
these two studies is whether all patients presenting with
CIS should be treated with disease-modifying therapy.
Not all patients with CIS progress in a similar fashion –
some will exhibit no further symptoms for many years,
while others will deteriorate more rapidly. However,
ways of predicting the likely course of disease in a given
patient population are currently limited. Initial lesion
load on MRI, and antibodies against myelin oligoden-
drocyte glycoprotein (MOG) and myelin basic protein
(MBP), as recently suggested by Berger [4], are the “hot
candidate markers”, but further studies are needed to
determine their practical value.
Emerging biotechniques in MS
MS – a highly complex and polygenic disorder – repre-
sents a formidable challenge to scientists developing
therapies. Identifying the specific genes responsible for
the pathogenesis of MS has been problematic not only
because of the large number of genes involved but also
because of the interactions between these genes and the
environment. While several effective therapies for MS
exist, individual patient response varies widely. Despite
these difficulties, regions of the genome contributing to
the susceptibility for MS have been located, and the in-
formation obtained from genetic studies may offer the
opportunity to define markers for disease susceptibility
and prognosis.
Pharmacogenetic and pharmacogenomic analyses
aim to identify markers that will predict patient re-
sponse to therapy and possible tolerability risks. Phar-
macogenetic studies try to characterise individual ge-
netic differences (at the DNA level) and understand how
this diversity causes variability in patients’ responses to
a specific treatment. Pharmacogenomics is the analysis
of gene expression (at the RNA level) and aims to iden-
tify markers relevant to treatment response.
A number of new, high-throughput techniques have
been developed, making it feasible to investigate a vast
number of genes and gene products simultaneously;
these techniques have significantly advanced the study
of various diseases.Although large-scale explorations of
gene expression have become routine over recent years,
the statistical and mathematical analyses of resulting
data is a developing discipline [9, 29, 41].
Comprehensive understanding of gene expression in
MS,both during treatment and the course of disease,can
help to identify genes that are important in drug re-
sponse and pathogenesis. However, measuring tran-
scriptional gene expression alone does not provide the
complete picture as, for example,post-transcriptional or
-translational modifications may process the protein
into a different form. Hence, proteomic studies that as-
sess the translation of processed RNA into proteins are
a critical accompaniment to genomic technologies
(Fig. 1).
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Genetic markers in MS
Single nucleotide polymorphisms (SNPs) are the most
common type of genetic variation. They occur with a
frequency of approximately 1 in 1000 nucleotides, and
there are approximately 10 million distributed through-
out the human genome. Only approximately 10–30 % of
SNPs are located within the coding regions of genes –
the vast majority are classed as “perigenic” and are situ-
ated in the non-coding and regulatory regions of genes.
The abundance of SNPs, coupled with the fact that they
are mutationally stable, makes them excellent gene-dis-
covery tools; SNPs associated with a particular pheno-
type can be used to pinpoint the responsible mutation.
To ensure proper diagnosis and treatment for pa-
tients with MS, markers that measure disease activity,
prognosis and response to treatment, and that can be
used as tools for evaluating clinical trials, are needed.
However, the organ affected by MS is not easily accessi-
ble using routine sampling methods,making isolation of
suitable markers difficult. In addition, candidate mark-
ers need to fulfil several requirements: a high degree of
reproducibility, be derived from a source suitable for re-
peated sampling (for example, from blood), and be ap-
plicable for use in routine clinical practice. Markers de-
rived from cerebrospinal fluid (CSF), such as an
endogenous pentapeptide showing promising results
[8], can be reliable indicators of the disease process, but
the problem is that CSF is an unsuitable source for re-
peated sampling. The search for suitable markers is on-
going in both animal models of MS and humans.
Gene expression profiling in MS
Gene expression profiling examines dynamic markers
(e. g. RNA and proteins), and the recent completion of
the Human Genome Project means that the capacity to
perform customised searches for differential gene ex-
pression now exists. Gene expression profiling can be
performed at the RNA or protein level via analytical
platforms called transcriptomics and proteomics, re-
spectively. Current high-throughput methods for simul-
taneously analysing the transcriptional expression of
thousands of genes include subtracted complimentary
DNA (cDNA) libraries, serial analysis of gene expression
(SAGE), differential display, quantitative reverse tran-
scription and polymerase chain reaction (RT-PCR) and
gene microarrays. These techniques have all been suc-
cessfully applied in MS research; for example,subtracted
cDNA libraries have been used to investigate the patho-
genesis of lesion development [3, 11], and dysregulation
of the inhibitory transcription factor sp3 was deter-
mined using the differential display technique [20]. The
most powerful and comprehensive techniques, however,
are microarrays and RT-PCR.
■ Microarrays
Microarrays, also referred to as DNA chips, are powerful
and versatile tools for genome analysis and exploit the
specific binding of complementary single-stranded nu-
cleic acid sequences. Use of gene chip microarrays pro-
vides a global approach to RNA expression profiling, as
they provide a high gene throughput (some can assess
the whole human genome in one experiment) and can
be used without well-defined underlying hypotheses.
Such “discovery-driven research” generates hypotheses,
in contrast to more conventional “hypothesis-driven re-
search”, which aims to confirm or reject a pre-existing
hypothesis.
cDNA microarrays usually contain double-stranded
cDNA sequences of interest that have been synthesised
by PCR. Oligonucleotide microarrays, however, are pre-
pared using specific oligonucleotides synthesised di-
rectly onto a quartz or silicon wafer using combinatorial
chemistry and photolithography [14, 16]. One microar-
ray may contain more than 1 million different oligonu-
cleotides.
Test samples, RNA isolated from the cells or tissue of
interest and control samples are labelled with a fluores-
cent dye and allowed to bind in a quantitative manner to
complementary sequences on the microarray. Relative
expression levels of the sequences in the test sample can
be estimated by comparing the fluorescence intensities,
measured by laser scanner, with those of the control
sample (see Fig. 2). In the case of MS, this process may
involve semi-quantitative screening of the whole
genome, using RNA from peripheral blood as the source
(whole blood or specific subpopulations of blood cells),
or cells from CSF obtained from a relatively small num-
ber of patients with MS. In both scenarios, samples from
patients who have and have not received various treat-
ments are needed.
Biological diversity
Genomes
Genes
RNA transcripts
Proteins
Other molecules
Sequencing
Annotation
Gene mapping
Proteomics
Expression
Structure
Metabolism
Fig. 1 The steps involved in functional genomics (from [43] with permission of
PAREXEL MMS Europe Ltd)
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■ RT-PCR
Genes that are differentially expressed in treated groups
compared with control groups can be analysed in more
detail and in larger numbers of patients using quantita-
tive real-time RT-PCR; this technique can analyse hun-
dreds of genes in a more quantitative fashion than mi-
croarrays. These investigations provide information on
the time course of the changes in expression of the genes
of interest during treatment, relative to baseline. Cell bi-
ology and DNA studies, as well as protein analysis, can
be undertaken in parallel in these samples. Markers that
appear to predict responses to therapy can then be sub-
jected to enzyme-linked immunosorbent assay (ELISA)
and further proteomic testing in a larger population of
patients. The rationale for this method of analysis has
been described by Martin et al. [34].
Proteomic techniques
Proteomics is an area of research that examines global
changes in protein expression. Technologies such as 2-
dimensional (2-D) gel electrophoresis + mass-spec-
trometry, bead-capture and micro-ELISA are proteomic
techniques currently employed successfully for drug
discovery and biomarker identification, mainly in the
field of oncology [10, 25].
Protein arrays, an emerging class of proteomic tech-
nologies, have great potential for acquiring information
about post-translational protein modifications that re-
flect the activity state of signal pathways and networks
involved in disease progression or remission [31]. Such
arrays have already been used for auto-antibody profil-
ing in autoimmune diseases, including MS [18, 23, 38].
Specialised “myelin proteome” arrays, containing hun-
dreds of proteins and peptides derived from the myelin
sheath, have been developed to study autoimmune re-
sponses in MS, but extensive validation is needed before
they could be used in routine clinical practice.
Clinical applications
■ Pharmacogenomics
In MS, the first published application of microarray
technology used brain samples from a patient with pri-
mary progressive MS [47]. In that study, 62 differentially
expressed genes were identified. To date, several large-
scale expression profiling studies on MS lesions and
normal appearing white matter (NAWM) have been per-
formed and have revealed a complex pattern of genes re-
lated to both inflammatory processes and unbalanced
immune response regulation [3, 11, 19, 30, 32, 35, 44,
47–48]. Microarray analysis of MS lesions obtained at
autopsy has also helped to elucidate MS pathology. One
study revealed up-regulation of granulocyte colony-
stimulating factor expression in acute but not chronic
lesions [32]. In contrast, immunoglobulin E receptor ex-
pression was up-regulated in chronic silent lesions com-
pared with acute lesions. These two genes were targeted
for therapy using the experimental autoimmune en-
cephalomyelitis mouse as a model of MS, and the results
corroborated the microarray studies on MS lesions [32].
Microarray technologies have been used to identify
prognostic and predictive markers for MS as well as
monitor treatment response. In a study of relapsing-re-
mitting MS (RRMS) using cDNA arrays from more than
4000 known human genes, 34 genes were found to be ex-
pressed at significantly different levels in MS patients
compared with control patients [37]. Based on the ex-
pression profiles of 6500–7500 genes, Bomprezzi et al.
[6] could distinguish between samples from RRMS pa-
tients and control individuals, and identify altered,
disease-relevant pathways in MS.
No definite treatment-response profile has been
identified in MS, but some effects of IFNβ and glati-
ramer acetate on gene expression have been described
[22, 28]. A comparison of gene expression profiles using
cDNA microarrays from patients with RRMS before and
after IFNβ-1b treatment demonstrated significant alter-
ations in the expression of 21 genes (from a total of
1263) in response to treatment. Nine of these genes con-
tained IFN-responsive promoter elements [28]. In gen-
eral, the effects of IFNβ on the gene expression profile
are complex and appear to influence many biological
processes, including cell migration, matrix degradation,
cell cycle control and cytokine and chemokine regula-
tion.For example,Wandinger et al. [46] found that IFNβ-
1b up-regulated expression of the chemokine receptor
CCR5 and the interleukin (IL)-12 receptor beta2 chain; it
also modulated the expression of a number of other
genes that may be relevant to MS.
mRNA Reference
AAA
RNA
Double-stranded cDNA
Biotin-labelled cRNA
Sample
AAAAAAA
AAAAAAA
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AAAAAAAPerfect match
Mismatch
In situ synthesis
by photolithography
Fig. 2 Schematic overview of oligonucleotide microarray technology (adapted
from [39], reproduced with permission of PAREXEL MMS Europe Ltd)
III/21_III/27_2013_JON_S_03/05  30.08.2005  10:58 Uhr  Seite 24
III/25
■ Proteomics
Proteomic techniques have been applied to clinical sam-
ples from patients with MS, such as CSF [15, 21]. Using
2-D gel electrophoresis followed by liquid chromatogra-
phy and mass spectrometry, 65 different proteins were
identified, 18 of which had not been reported previously
[15]. However, the relevance of these proteins to MS
needs further evaluation.
■ Pharmacogenomics
Genomic studies have generated useful data highlight-
ing the potential pathogenetic mechanisms involved in
MS, and allow better insights into the mode of action
and efficacy of various treatments. However, expression
profiling results need to be combined with well-docu-
mented clinical and imaging data to maximise interpre-
tation.
Genetic information must be associated with clinical
data on treatment response; these data can only be gen-
erated from therapeutic trials with regular clinical and
MRI monitoring that include pharmacogenomic analy-
ses in their design. One study of a patient with MS
treated with IFNβ-1b detected altered gene expression
using a cDNA microarray derived from peripheral
blood mononuclear cells (PBMCs); these changes were
correlated with MRI changes [46]. In another study,
Sturzebecher et al. [42] made an initial attempt to corre-
late gene expression changes in response to treatment
with treatment response as assessed by MRI. This group
compared the gene expression profiles, using cDNA mi-
croarrays, of patients who responded to IFNβ-1b with
those who either initially responded and then became
non-responders, or who were not responsive to treat-
ment. The results of the study, albeit based on limited
numbers of patients, showed that there were definite dif-
ferences in the gene expression profiles of treatment-re-
sponsive and non-treatment-responsive patients.
■ Therapeutic studies with IFNβ-1b
Two studies with IFNβ-1b, BENEFIT (BEtaferon®/Be-
taseron® in Newly Emerging MS For Initial Treatment)
and BEST-PGx (Betaferon®/Betaseron® in Early RRMS
Surveillance Trial – Pharmacogenomics), have been de-
signed to examine the long-term effects of early treat-
ment on the course of MS.
■ BENEFIT
The BENEFIT (BEtaseron®/Betaferon®) study is the first
to examine the effects of conventional, high-dose, high-
frequency IFNβ-1b administration in patients with CIS
and MRI evidence of disease, in terms of the time to a
second clinical event and, hence, a diagnosis of CDMS
[17]. BENEFIT will also examine the long-term benefits
of treatment beyond effects on the second clinical event.
BENEFIT consists of a 2-year, randomised, double-
blind, placebo-controlled, parallel-group study and a 3-
year, open-label, follow-up study. In this study, a total of
487 patients have been randomised to either IFNβ-1b
250 µg (8 MIU) subcutaneously every other day, or
placebo in a ratio of 5:3. Patients fulfilling the two pri-
mary endpoints (time to diagnosis of MS using the Mc-
Donald et al. [33] criteria and time to diagnosis of CDMS
using the Poser criteria [36]) will be offered treatment
with IFNβ-1b in the open-label part of the study. In ad-
dition, all patients completing the 2-year study without
fulfilling the primary endpoints will also be offered
open-label IFNβ-1b treatment. The open-label study
will compare the efficacy of treatment initiated after the
first clinical event with that initiated after conversion to
CDMS.
Exploratory analysis of molecular prognostic factors
will be undertaken. This will include expression profil-
ing and pharmacogenetic analyses (the latter being op-
tional and requiring separate informed consent). Blood
samples will be taken from these patients at all sched-
uled visits, and samples for RNA analysis will be ob-
tained at pre-defined points during the initial 2-year
study and the follow-up study.
■ BEST-PGx
BEST-PGx is an exploratory, 2-year, investigator-led, ob-
servational study investigating the value of RNA expres-
sion profiling (and also pharmacogenetics in one sub-
group) for predicting treatment response to IFNβ in
patients with early RRMS [26]. The main goal of BEST-
PGx is to identify differences in gene expression profiles
in patients showing differential treatment responses. In
addition,this study may reveal new information relevant
to the mechanism of action of IFNβ treatment in MS,but
also to differences in the underlying pathology of the
immune system in different subgroups of patients.
Conclusions
The pharmacogenomic outcomes of the BENEFIT and
BEST-PGx studies will allow some progress towards in-
dividualised medicine for patients and, in the process,
offer insights into the effective integration of these new
technologies into the current clinical trial paradigm.
It is hoped that pharmacogenomics will ultimately al-
low profiling of patients with MS according to their
course of disease and their likely response to a particu-
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lar treatment. The definition of molecular markers for
MS will possibly allow detailed prediction of the need of
a patient for therapy, and a patient’s response to relevant
aspects of pharmacotherapy, including response to
treatment and adverse effects. Using this information, it
should be possible to provide individualised therapy to
ensure that a patient obtains the most appropriate treat-
ment from the outset. This approach is expected to in-
crease overall treatment efficacy, reduce adverse drug
reactions and allow more efficient use of healthcare re-
sources.
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